GA management involves identifying at-risk patients, assessing visual function, and referring for treatment when necessary.

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.0, along with a high estimate of $9.00 and a low estimate of $2.00. No alteration is ...

Age-related macular degeneration (AMD ... by administering them as eye drops to mice with induced dry AMD. The treated group exhibited retinal cell protection and significantly reduced retinal ...

A 2015 paper, published in Pathobiology of Aging and Age-related Diseases, calls zinc an "essential micronutrient for human health in general, and particularly for the elderly." The authors say ...

Retinitis pigmentosa is a rare visual disorder that affects a layer of tissue in the back of the eye known as the retina—shown ... below a layer of retinal pigment epithelium cells.

There’s a big ‘if’ though: Opthea’s two phase III trials for the debilitating wet aged-related macular degeneration (wet AMD) need to come up trumps. (Refer to item one for ‘risk factors ...